Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
Department of Psychiatry and Human Behavior, Brown University School of Medicine, Rhode Island Hospital, Providence, RI, USA
Список исп. литературыСкрыть список 1. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, 3rd ed. Washington: American Psychiatric Association, 2010. 2. National Collaborating Centre for Mental Health. Depression: the treatment and management of depression in adults. London: National Institute for Health and Clinical Excellence, 2009. 3. Tyrer P, Crawford M, Mulder R et al. Reclassifying personality disorders. Lancet 2011;377:1814-5. 4. Tyrer P, Crawford M, Mulder R et al. The rationale for the reclassification of personality disorder in the 11th revision of the International Classification of Diseases (ICD-11). Personal Ment Health 2011;5:246-59. 5. Minichiello E, Semerano L, Boissier MC. Time trends in the incidence, prevalence, and severity of rheumatoid arthritis: a systematic literature review. Joint Bone Spine 2016;83:625-30. 6. Hirai FE, Tielsch JM, Klein BE et al. Relationship between retinopathy severity, visual impairment and depression in persons with long-term type 1 diabetes. Ophthalmic Epidemiol 2012;19:196-203. 7. Greco A, Steca P, Pozzi R et al. Predicting depression from illness severity in cardiovascular disease patients: self-efficacy beliefs, illness perception, and perceived social support as mediators. Int J Behav Med 2014;21:221-9. 8. Steca P, Greco A, Monzani D et al. How does illness severity influence depression, health satisfaction and life satisfaction in patients with cardiovascular disease? The mediating role of illness perception and self-efficacy beliefs. Psychol Health 2013;28:765-83. 9. Pelletier R, Lavoie KL, Bacon SL et al. Depression and disease severity in patients with premature acute coronary syndrome. Am J Med 2014;127:87-93. 10. Carels RA. The association between disease severity, functional status, depression and daily quality of life in congestive heart failure patients. Qual Life Res 2004;13:63-72. 11. Snell C, Fernandes S, Bujoreanu IS et al. Depression, illness severity, and healthcare utilization in cystic fibrosis. Pediatr Pulmonol 2014;49:1177-81. 12. Deterding K, Gruner N, Buggisch P et al. Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity. Eur J Gastroenterol Hepatol 2016;28:187-92. 13. Euesden J, Matcham F, Hotopf M et al. The relationship between mental health, disease severity, and genetic risk for depression in early rheumatoid arthritis. Psychosom Med 2017;79:638-45. 14. Reynolds JC, Rittenberger JC, Toma C et al. Risk-adjusted outcome prediction with initial post-cardiac arrest illness severity: implications for cardiac arrest survivors being considered for early invasive strategy. Resuscitation 2014;85:1232-9. 15. Coppler PJ, Elmer J, Calderon L et al. Validation of the Pittsburgh Cardiac Arrest Category illness severity score. Resuscitation 2015;89:86-92. 16. Schaeffer JJ, Gil KM, Burchinal M et al. Depression, disease severity, and sickle cell disease. J Behav Med 1999;22:115-26. 17. Kim KU, Park HK, Jung HY et al. Association of depression with disease severity in patients with chronic obstructive pulmonary disease. Lung 2014;192:243-9. 18. van Dijk JP, Havlikova E, Rosenberger J et al. Influence of disease severity on fatigue in patients with Parkinson’s disease is mainly mediated by symptoms of depression. Eur Neurol 2013;70:201-9. 19. Goetz CG, Tilley BC, Shaftman SR et al. Movement Disorder Societysponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-70. 20. Bennett JA, Riegel B, Bittner V et al. Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease. Heart Lung 2002;31:262-70. 21. Knaus WA, Zimmerman JE, Wagner DP et al. APACHE-acute physiology and chronic health evaluation: a physiologically based classification system. Crit Care Med 1981;9:591-7. 22. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993;270:2957-63. 23. de Groot B, de Deckere ER, Flameling R et al. Performance of illness severity scores to guide disposition of emergency department patients with severe sepsis or septic shock. Eur J Emerg Med 2012;19:316-22. 24. Schneider AG, Lipcsey M, Bailey M et al. Simple translational equations to compare illness severity scores in intensive care trials. J Crit Care 2013;28:e881-8. 25. Barry MJ, Fowler FJ Jr, O’Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 2017;197:S189-97. 26. Folmer RL, Shi YB. SSRI use by tinnitus patients: interactions between depression and tinnitus severity. Ear Nose Throat J 2004;83:107-8. 27. Gros DF, Antony MM, McCabe RE et al. Frequency and severity of the symptoms of irritable bowel syndrome across the anxiety disorders and depression. J Anxiety Disord 2009;23:290-6. 28. Stewart WF, Lipton RB, Simon D et al. Validity of an illness severity measure for headache in a population sample of migraine sufferers. Pain 1999;79:291-301. 29. Baker GA, Smith DF, Jacoby A et al. Liverpool Seizure Severity Scale revisited. Seizure 1998;7:201-5. 30. Clark JA, Spiro A, Miller DR et al. Patient-based measures of illness severity in the Veterans Health Study. J Ambul Care Manage 2005;28:274-85. 31. Slade M, Powell R, Strathdee G. Current approaches to identifying the severely mentally ill. Soc Psychiatry Psychiatr Epidemiol 1997;32:177-84. 32. Ruggeri M, Leese M, Thornicroft G et al. Definition and prevalence of severe and persistent mental illness. Br J Psychiatry 2000;177:149-55. 33. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed. Arlington: American Psychiatric Association, 2013. 34. Fattori A, Neri L, Bellomo A et al. Depression severity and concentration difficulties are independently associated with HRQOL in patients with unipolar depressive disorders. Qual Life Res 2017;26:2459-69. 35. Goethe JW, Fischer EH, Wright JS. Severity as a key construct in depression. J Nerv Ment Dis 1993;181:718-24. 36. Luty SE, Joyce PR, Mulder RT et al. Social adjustment in depression: the impact of depression severity, personality, and clinic versus community sampling. J Affect Disord 2002;70:143-54. 37. Bradvik L, Mattisson C, Bogren M et al. Long-term suicide risk of depression in the Lundby cohort 1947-1997 – severity and gender. Acta Psychiatr Scand 2008;117:185-91. 38. Kessing LV. Severity of depressive episodes according to ICD-10: prediction of risk of relapse and suicide. Br J Psychiatry 2004;184:153-6. 39. Wang YY, Jiang NZ, Cheung EF et al. Role of depression severity and impulsivity in the relationship between hopelessness and suicidal ideation in patients with major depressive disorder. J Affect Disord 2015;183:83-9. 40. Katon W, Unutzer J, Russo J. Major depression: the importance of clinical characteristics and treatment response to prognosis. Depress Anxiety 2010;27:19-26. 41. Keller MB, Lavori PW, Mueller TI et al. Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992;49:809-16. 42. Meyers BS, Sirey JA, Bruce M et al. Predictors of early recovery from major depression among persons admitted to community-based clinics: an observational study. Arch Gen Psychiatry 2002;59:729-35. 43. Melartin T, Rytsala H, Leskela U et al. Severity and comorbidity predict episode duration and recurrence of DSM-IV major depressive disorder. J Clin Psychiatry 2004;65:810-9. 44. Berent D, Zboralski K, Orzechowska A et al. Thyroid hormones association with depression severity and clinical outcome in patients with major depressive disorder. Mol Biol Rep 2014;41:2419-25. 45. de Diego-Adelino J, Pires P, Gomez-Anson B et al. Microstructural whitematter abnormalities associated with treatment resistance, severity and duration of illness in major depression. Psychol Med 2014;44:1171-82. 46. Zimmerman M, Coryell W, Pfohl B. The validity of the dexamethasone suppression test as a marker for endogenous depression. Arch Gen Psychiatry 1986;43:347-55. 47. Lux V, Aggen SH, Kendler KS. The DSM-IV definition of severity of major depression: inter-relationship and validity. Psychol Med 2010;40:1691-701. 48. Faravelli C, Servi P, Arends J et al. Number of symptoms, quantification, and qualification of depression. Compr Psychiatry 1996;37:307-15. 49. Guy W. ECDEU assessment manual for psychopharmacology. Rockville: National Institute of Mental Health, 1976. 50. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington: American Psychiatric Association, 1994. 51. Kitamura T, Nakagawa Y, Machizawa S. Grading depression severity by symptom scores: is it a valid method for subclassifying depressive disorders? Compr Psychiatry 1993;34:280-3. 52. Kessler RC, Zhao S, Blazer DG et al. Prevalence, correlates, and course of minor depression and major depression in the National Comorbidity Survey. J Affect Disord 1997;45:19-30. 53. Wakefield JC, Schmitz MF. Severity of complicated versus uncomplicated subthreshold depression: new evidence on the “monotonicity thesis” from the National Comorbidity Survey. J Affect Disord 2017;212:101-9. 54. Wakefield JC, Schmitz MF. Symptom quality versus quantity in judging prognosis: using NESARC predictive validators to locate uncomplicated major depression on the number-of-symptoms severity conti-nuum. J Affect Disord 2017;208:325-9. 55. World Health Organization. International classification of diseases and related health problems, 10th revision. Geneva: World Health Organization, 2016. 56. Hiller W, Dichtl G, Hecht H et al. Evaluating the new ICD-10 categories of depressive episode and recurrent depressive disorder. J Affect Disord 1994;31:49-60. 57. Montgomery S. Are the ICD-10 or DSM-5 diagnostic systems able to define those who will benefit from treatment for depression? CNS Spectr 2016;21:283-8. 58. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62. 59. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9. 60. Nemeroff CB. The burden of severe depression: a review of diagnostic challenges and treatment alternatives. J Psychiatr Res 2007;41:189-206. 61. Sonawalla SB, Fava M. Severe depression: is there a best approach? CNS Drugs 2001;15:765-76. 62. Williams JB, Kobak KA, Bech P et al. The GRID-HAMD: standardization of the Hamilton Depression Rating Scale. Int Clin Psychopharmacol 2008;23:120-9. 63. Parker G, Hadzi-Pavlovic D, Sengoz A et al. A brief self-report depression measure assessing mood state and social impairment. J Affect Disord 1994;30:133-42. 64. Pilkonis PA, Choi SW, Reise SP et al. Item banks for measuring emotional distress from the Patient-Reported Outcomes Measurement Information System (PROMIS): depression, anxiety, and anger. Assessment 2011;18:263-83. 65. Balsamo M, Giampaglia G, Saggino A. Building a new Rasch-based selfreport inventory of depression. Neuropsychiatr Dis Treat 2014;10:153-65. 66. Vaccarino AL, Evans KR, Kalali AH et al. The Depression Inventory Development Workgroup: a collaborative, empirically driven initiative to develop a new assessment tool for major depressive disorder. Innov Clin Neurosci 2016;13:20-31. 67. Zimmerman M, Posternak M, Friedman M et al. Which factors influence psychiatrists’ selection of an antidepressant? Am J Psychiatry 2004;161:1285-9. 68. Cheung HN, Power MJ. The development of a new multidimensional depression assessment scale: preliminary results. Clin Psychol Psychother 2012;19:170-8. 69. Licht RW, Qvitzau S, Allerup P et al. Validation of the Bech-Rafaelsen Melancholia Scale and the Hamilton Depression Scale in patients with major depression; is the total score a valid measure of illness severity? Acta Psychiatr Scand 2005;111:144-9. 70. Santor D, Coyne J. Examining symptom expression as a function of symptom severity: item performance on the Hamilton Rating Scale for Depression. Psychol Assess 2001;13:127-39. 71. Kroenke K, Spitzer R, Williams J. The PHQ-9. Validity of a brief depression severity measure. J Gen Int Med 2001;16:606-13. 72. Downey L, Hayduk LA, Curtis JR et al. Measuring depression-severity in critically ill patients’ families with the Patient Health Questionnaire (PHQ): tests for unidimensionality and longitudinal measurement invariance, with implications for CONSORT. J Pain Sympt Manage 2016;51:938-46. 73. Fischer HF, Tritt K, Klapp BF et al. How to compare scores from different depression scales: equating the Patient Health Questionnaire (PHQ) and the ICD-10-Symptom Rating (ISR) using item response theory. Int J Methods Psychiatr Res 2011;20:203-14. 74. Adler M, Hetta J, Isacsson G et al. An item response theory evaluation of three depression assessment instruments in a clinical sample. BMC Med Res Methodol 2012;12:84. 75. Barthel D, Barkmann C, Ehrhardt S et al. Screening for depression in pregnant women from Cote d’Ivoire and Ghana: psychometric properties of the Patient Health Questionnaire-9. J Affect Disord 2015;187:232-40. 76. Pedersen SS, Mathiasen K, Christensen KB et al. Psychometric analysis of the Patient Health Questionnaire in Danish patients with an implantable cardioverter defibrillator (The DEFIB-WOMEN study). J Psychosom Res 2016;90:105-12. 77. Umegaki Y, Todo N. Psychometric properties of the Japanese CES-D, SDS, and PHQ-9 depression scales in university students. Psychol Assess 2017;29:354-9. 78. Zhong Q, Gelaye B, Fann JR et al. Cross-cultural validity of the Spanish version of PHQ-9 among pregnant Peruvian women: a Rasch item response theory analysis. J Affect Disord 2014;158:148-53. 79. Zimmerman M, Chelminski I, McGlinchey JB et al. A clinically useful depression outcome scale. Compr Psychiatry 2008;49:131-40. 80. Zimmerman M, Galione J, Attiullah N et al. Depressed patients perspectives of two measures of outcome: the Quick Inventory of Depressive Symptomatology (QIDS) and the Remission from Depression Questionnaire (RDQ). Ann Clin Psychiatry 2011;23:208-12. 81. Bentley KH, Gallagher MW, Carl JR et al. Development and validation of the Overall Depression Severity and Impairment Scale. Psychol Assess 2014;26:815-30. 82. Bagby RM, Ryder AG, Schuller DR et al. The Hamilton Depression Rating Scale: has the gold standard become a lead weight? Am J Psychiatry 2004;161:2163-77. 83. Zimmerman M, Posternak M, Chelminski I. Is it time to replace the Hamilton Depression Rating Scale as the primary outcome measure in treatment studies of depression? J Clin Psychopharmacol 2005;25:105-10. 84. Tiplady B. A self-rating scale for depression designed to be sensitive to change. Neuropharmacology 1980;19:1211-2. 85. Rush A, Trivedi M, Ibrahim H et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003;54:573-83. 86. Olsen LR, Jensen DV, Noerholm V et al. The internal and external validity of the Major Depression Inventory in measuring severity of depressive states. Psychol Med 2003;33:351-6. 87. Rush AJ, Gullion CM, Basco MR et al. The Inventory of Depressive Symptomatology (IDS). Psychol Med 1996;26:477-86. 88. Moller HJ. Methodological aspects in the assessment of severity of depression by the Hamilton Depression Scale. Eur Arch Psychiatry Clin Neurosci 2001;251(Suppl. 2):13-20. 89. DeRubeis RJ, Gelfand LA, Tang TZ et al. Medications versus cognitive behavior therapy for severely depressed outpatients: mega-analysis of four randomized comparisons. Am J Psychiatry 1999;156:1007-13. 90. Gibbons R, Hur K, Brown C et al. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry 2012;69:572-9. 91. Elkin I, Gibbons R, Shea M et al. Initial severity and differential treatment outcome in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. J Consult Clin Psychol 1995;63:841-7. 92. Kirsch I, Deacon BJ, Huedo-Medina TB et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008;5:260-8. 93. Rush AJ, First MB, Blacker D. Handbook of psychiatric measures, 2nd ed. Washington: American Psychiatric Publishing, 2008. 94. Khan A, Leventhal RM, Khan SR et al. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 2002;22:40-5. 95. Fournier JC, DeRubeis RJ, Hollon SD et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010;303:47-53. 96. Dunner D, Lipschitz A, Pitts C et al. Efficacy and tolerability of controlledrelease paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials. Clin Ther 2005;27:1901-11. 97. Kasper S. Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine. J Clin Psychopharmacol 1997;17(Suppl. 1):19S-28S. 98. Montgomery S, Ferguson J, Schwartz G. The antidepressant efficacy of reboxetine in patients with severe depression. J Clin Psychopharmacol 2003;23:45-50. 99. Schmitt AB, Bauer M, Volz HP et al. Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity. Eur Arch Psychiatry Clin Neurosci 2009;259:329-39. 100. Shelton RC, Prakash A, Mallinckrodt CH et al. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. Int J Clin Pract 2007;61:1337-48. 101. Versiani M, Moreno R, Ramakers-van Moorsel C et al. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs 2005;19:137-46. 102. Hirschfeld R. Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. J Clin Psychiatry 1999;60:326-35. 103. Montgomery S, Lecrubier Y. Is severe depression a separate indication? Eur Neuropsychopharmacol 1999;9:259-64. 104. Schatzberg AF. Antidepressant effectiveness in severe depression and melancholia. J Clin Psychiatry 1999;60(Suppl. 4):14-21. 105. Endicott J, Cohen J, Nee J et al. Hamilton depression rating scale. Arch Gen Psychiatry 1981;38:98-103. 106. Kearns NP, Cruickshank CA, McGuigan KJ et al. A comparison of depression rating scales. Br J Psychiatry 1982;141:45-9. 107. Cameron IM, Cardy A, Crawford JR et al. Measuring depression severity in general practice: discriminatory performance of the PHQ-9, HADS-D, and BDI-II. Br J Gen Pract 2011;61:e419-26. 108. Zimmerman M, Martinez JH, Young D et al. Severity classification on the Hamilton Depression Rating Scale. J Affect Disord 2013;150:384-8. 109. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361-70. 110. Cameron IM, Crawford JR, Lawton K et al. Psychometric comparison of PHQ-9 and HADS for measuring depression severity in primary care. Br J Gen Pract 2008;58:32-6. 111. Hansson M, Chotai J, Nordstom A et al. Comparison of two self-rating scales to detect depression: HADS and PHQ-9. Br J Gen Pract 2009;59: e283-8. 112. Reddy P, Philpot B, Ford D et al. Identification of depression in diabetes: the efficacy of PHQ-9 and HADS-D. Br J Gen Pract 2010;60:e239-45. 113. Beck A, Steer R, Brown G. The Beck Depression Inventory, 2nd ed. San Antonio: The Psychological Corporation, 1996. 114. Zimmerman M, Martinez J, Friedman M et al. How can we use depression severity to guide treatment selection when measures of depression categorize patients differently? J Clin Psychiatry 2012;73:1287-91. 115. Ruscio J, Zimmerman M, McGlinchey JB et al. Diagnosing major depressive disorder XI: a taxometric investigation of the structure underlying DSM-IV symptoms. J Nerv Ment Dis 2007;195:10-9. 116. van der Lem R, van der Wee NJ, van Veen T et al. The generalizability of antidepressant efficacy trials to routine psychiatric out-patient practice. Psychol Med 2011;41:1353-63. 117. Bielski RJ, Friedel RO. Prediction of tricyclic antidepressant response: a critical review. Arch Gen Psychiatry 1976;33:1479-89. 118. Grammer GG, Kuhle AR, Clark CC et al. Severity of depression predicts remission rates using transcranial magnetic stimulation. Front Psychiatry 2015;6:114. 119. Jones NP, Siegle GJ, Thase ME. Effects of rumination and initial severity on remission to cognitive therapy for depression. Cogn Ther Res 2008;32:591-604. 120. Lisanby SH, Husain MM, Rosenquist PB et al. Daily left prefrontal repetitive transcranial magnetic stimulation in the acute treatment of major depression: clinical predictors of outcome in a multisite, randomized controlled clinical trial. Neuropsychopharmacology 2009;34:522-34. 121. Bower P, Kontopantelis E, Sutton A et al. Influence of initial severity of depression on effectiveness of low intensity interventions: meta-analysis of individual patient data. BMJ 2013;346:f540. 122. Sugawara Y, Higuchi H, Yoshida K et al. Response rate obtained using milnacipran depending on the severity of depression in the treatment of major depressive patients. Clin Neuropharmacol 2006;29:6-9. 123. Friedman ES, Davis LL, Zisook S et al. Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial. Eur Neuropsychopharmacol 2012;22:183-99. 124. Kennedy S, Andersen H, Lam R. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine SR: a meta-analysis. J Psychiatry Neurosci 2006;31:122-31. 125. Angst J, Amrein R, Stabl M. Moclobemide and tricyclic antidepressants in severe depression: meta-analysis and prospective studies. J Clin Psychopharmacol 1995;15:16S-23S. 126. Wiles NJ, Mulligan J, Peters TJ et al. Severity of depression and response to antidepressants: GENPOD randomised controlled trial. Br J Psychiatry 2011;200:130-6. 127. Kilts CD, Wade AG, Andersen HF et al. Baseline severity of depression predicts antidepressant drug response relative to escitalopram. Exp Opin Pharmacother 2009;10:927-36. 128. Khan A, Sambunaris A, Edwards J et al. Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression. Int Clin Psychopharmacol 2014;29:86-92. 129. Mosca D, Zhang M, Prieto R et al. Efficacy of desvenlafaxine compared with placebo in major depressive disorder patients by age group and severity of depression at baseline. J Clin Psychopharmacol 2017;37:182-92. 130. Driessen E, Cuijpers P, Hollon SD et al. Does pretreatment severity moderate the efficacy of psychological treatment of adult outpatient depression? A meta-analysis. J Consult Clin Psychol 2010;78:668-80. 131. Furukawa TA, Weitz ES, Tanaka S et al. Initial severity of depression and efficacy of cognitive-behavioural therapy: individual-participant data metaanalysis of pill-placebo-controlled trials. Br J Psychiatry 2017;210:190-6. 132. Guelfi JD, Ansseau M, Timmerman L et al. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 2001;21:425-31. 133. Henkel V, Seemuller F, Obermeier M et al. Relationship between baseline severity of depression and antidepressant treatment outcome. Pharmacopsychiatry 2011;44:27-32. 134. Hirschfeld RM, Russell JM, Delgado PL et al. Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. J Clin Psychiatry 1998;59:669-75. 135. Madhoo M, Levine SZ. Initial severity effects on residual symptoms in response and remission: a STAR*D study during and after failed citalopram treatment. J Clin Psychopharmacol 2015;35:450-3. 136. Souery D, Oswald P, Massat I et al. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry 2007;68:1062-70. 137. Brown C, Schulberg HC, Prigerson HG. Factors associated with symptomatic improvement and recovery from major depression in primary care patients. Gen Hosp Psychiatry 2000;22:242-50. 138. Enns MW, Cox BJ. Psychosocial and clinical predictors of symptom persistence vs. remission in major depressive disorder. Can J Psychiatry 2005;50:769-77. 139. Sargeant JK, Bruce ML, Florio LP et al. Factors associated with 1-year outcome of major depression in the community. Arch Gen Psychiatry 1990;47:519-26. 140. Turner EH, Matthews AM, Linardatos E et al. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60. 141. Rabinowitz J, Werbeloff N, Mandel FS et al. Initial depression severity and response to antidepressants vs. placebo: patient-level data analysis from 34 randomised controlled trials. Br J Psychiatry 2016;209:427-8. 142. Elkin I, Shea M, Watkins J et al. NIMH treatment of depression collaborative research program: general effectiveness of treatments. Arch Gen Psychiatry 1989;46:971-82. 143. Cuijpers P, van Straten A, van Oppen P et al. Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies. J Clin Psychiatry 2008;69:1675-85. 144. Weitz ES, Hollon SD, Twisk J et al. Baseline depression severity as moderator of depression outcomes between cognitive behavioral therapy vs. pharmacotherapy: an individual patient data meta-analysis. JAMA Psychiatry 2015;72:1102-9. 145. Links PS, Eynan R. The relationship between personality disorders and Axis I psychopathology: deconstructing comorbidity. Annu Rev Clin Psychol 2013;9:529-54. 146. Lenzenweger MF, Lane MC, Loranger AW et al. DSM-IV personality disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007;62:553-64. 147. Bateman AW, Fonagy P. The effectiveness of partial hospitalization in the treatment of borderline personality disorder – a randomised controlled trial. Am J Psychiatry 1999;156:1563-9. 148. National Collaborating Centre for Mental Health. Borderline personality disorder: recognition and management. London: Department of Health, 2009. 149. Blum N, St John D, Pfohl B et al. Systems Training for Emotional Predictability and Problem Solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up. Am J Psychiatry 2008;165:468-78. 150. Zanarini MC, Yong L, Frankenburg FR et al. Severity of childhood sexual abuse and its relationship to severity of borderline psychopathology and psychosocial impairment among borderline inpatients. J Nerv Ment Dis 2002;190:381-7. 151. Giesen-Bloo JH, Wachters LM, Schouten E et al. The borderline personality disorder severity index-IV: psychometric evaluation and dimensional structure. Pers Ind Diff 2010;49:136-41. 152. Yang M, Coid J, Tyrer P. Personality pathology recorded by severity: national survey. Br J Psychiatry 2010;197:193-9. 153. Tyrer P, Alexander MS, Cicchetti D et al. Reliability of a schedule for rating personality disorders. Br J Psychiatry 1979;135:168-74. 154. Dolan B, Evans C, Norton K. Multiple axis-II diagnoses of personality disorder. Br J Psychiatry 1995;166:107-12. 155. Oldham JM, Skodol AE, Kellman HD et al. Diagnosis of DSM-III-R personality disorders by two structured interviews: patterns of comorbidity. Am J Psychiatry 1992;149:213-20. 156. Zimmerman M, Galione JN, Chelminski I et al. Does the diagnosis of multiple Axis II disorders have clinical significance? Ann Clin Psychiatry 2012;24:195-201. 157. Tyrer P, Johnson T. Establishing the severity of personality disorder. Am J Psychiatry 1996;153:1593-7. 158. Asnaani A, Chelminski I, Young D et al. Heterogeneity of borderline personality disorder: do the number of criteria met make a difference? J Pers Disord 2007;21:615-25. 159. Kernberg OF, Caligor E. A psychoanalytic theory of personality disorders. In: Clarkin JF, Lenzenweger MF (eds). Major theories of personality disorder. New York: Guilford, 2005:114-56. 160. Paris J. Dimensional diagnosis and the DSM-5. J Clin Psychiatry 2005;72:1340. 161. Moran P. Dangerous severe personality disorder – bad tidings from the UK. Int J Soc Psychiatry 2001;48:6-10. 162. Maden A, Tyrer P. Dangerous and severe personality disorders: a new personality concept from the United Kingdom. J Pers Disord 2003;17:489-96. 163. Tyrer P, Cooper S, Rutter D et al. The assessment of dangerous and severe personality disorder: lessons from a randomised controlled trial linked to qualitative analysis. Forensic Psychol Psychiatry 2009;20:132-46. 164. Berghuis H, Kamphuis JH, Verheul R. Specific personality traits and general personality dysfunction as predictors of the presence and severity of personality disorders in a clinical sample. J Pers Assess 2014;96:410-6. 165. Crawford MJ, Koldobsky N, Mulder R et al. Classifying personality disorder according to severity. J Pers Disord 2011;25:321-30. 166. Livesley WJ. Practical management of personality disorders. New York: Guilford, 2003. 167. Widiger TA, Costa PT, McCrae RR. A proposal for Axis II: diagnosing personality disorders using the five factor model. In: Costa PT, Widiger TA (eds). Personality disorders and the five factor model of personality. Washington: American Psychological Association, 2002:431-52. 168. Widiger TA, Mullins-Sweatt SN. Five-factor model of personality disorder: a proposal for DSM-V. Annu Rev Clin Psychol 2009;5:197-220. 169. Widiger TA, Trull TJ. Plate tectonics in the classification of personality disorder: shifting to a dimensional model. Am Psychol 2007;62: 71-83. 170. Livesley W, Schroeder M, Jackson D et al. Categorical distinctions in the study of personality disorder: implications for classification. J Abnorm Psychol 1994;103:6-17. 171. Parker G, Hadzi-Pavlovic D, Both L et al. Measuring disordered personality functioning: to love and to work reprised. Acta Psychiatr Scand 2004;110:230-9. 172. Trull TJ. Dimensional models of personality disorder: coverage and cutoffs. J Pers Disord 2005;19:262-82. 173. Verheul R, Andrea H, Berghout CC et al. Severity Indices of Personality Problems (SIPP-118): development, factor structure, reliability, and validity. Psychol Assess 2008;20:23-34. 174. Livesley WJ. Suggestions for a framework for an empirically based classification of personality disorder. Can J Psychiatry 1998;43: 137-47. 175. Ro E, Clark LA. Interrelations between psychosocial functioning and adaptive- and maladaptive-range personality traits. J Abnorm Psychol 2013;122:822-35. 176. Krueger RF, Derringer J, Markon KE et al. Initial construction of a maladaptive personality trait model and inventory for DSM-5. Psychol Med 2012;42:1879-90. 177. Gunderson J, Zanarini MC. Commentary: deceptively simple – or radical shift? Pers Ment Health 2011;5:260-2. 178. Kelly BD, Nur UA, Tyrer P et al. Impact of severity of personality disorder on the outcome of depression. Eur Psychiatry 2009;24:322-6. 179. Livesley WJ. General Assessment of Personality Disorder (GAPD). Vancouver: University of British Columbia, 2006. 180. Berghuis H, Kamphuis JH, Verheul R. Core features of personality disorder: differentiating general personality dysfunctioning from personality traits. J Pers Disord 2012;26:704-16. 181. Berghuis H, Kamphuis JH, Verheul R et al. The General Assessment of Personality Disorder (GAPD) as an instrument for assessing the core features of personality disorders. Clin Psychol Psychother 2013;20:544-57. 182. Arntz A, van den Hoorn M, Cornelis J et al. Reliability and validity of the borderline personality disorder severity index. J Pers Disord 2003;17:45-59. 183. Clarkin JF, Levy KN, Lenzenweger MF et al. Evaluating three treatments for borderline personality disorder: a multiwave study. Am J Psychiatry 2007;164:922-8. 184. Linehan MM, Comtois KA, Murray AM et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs. therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry 2006;63:757-66. 185. Zanarini MC, Vujanovic AA, Parachini EA et al. Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology. J Pers Disord 2003;17:233-42. 186. Patton JH, Stanford MS, Barratt ES. Factor structure of the Barratt Impulsiveness Scale. J Clin Psychol 1995;51:768-74. 187. Doering S, Horz S, Rentrop M et al. Transference-focused psychotherapy v. treatment by community psychotherapists for borderline personality disorder: randomised controlled trial. Br J Psychiatry 2010;196:389-95. 188. McMain SF, Links PS, Gnam WH et al. A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. Am J Psychiatry 2009;166:1365-74. 189. Diamond D, Yeomans FE, Stern B et al. Transference focused psychotherapy for patients with comorbid narcissistic and borderline personality disorder. Psychoanal Inq 2013;33:527-51. 190. Messina NP, Wish ED, Hoffman JA et al. Antisocial personality disorder and treatment outcomes. Am J Drug Alcohol Abuse 2002;28:197-212. 191. Kotov R, Krueger RF, Watson D et al. The Hierarchical Taxonomy of Psychopathology (HiTOP): a dimensional alternative to traditional nosologies. J Abnorm Psychol 2017;126:454-77. 192. Stanton K, Rozek DC, Stasik-O’Brien SM et al. A transdiagnostic approach to examining the incremental predictive power of emotion regulation and basic personality dimensions. J Abnorm Psychol 2016;125:960-75. 193. Zimmerman M. A review of 20 years of research on overdiagnosis and underdiagnosis in the Rhode Island Methods to Improve Diagnostic Assessment and Services (MIDAS) project. Can J Psychiatry 2016;61:71-9. 194. Krueger RF, Finger MS. Using item response theory to understand comorbidity among anxiety and unipolar mood disorders. Psychol Assess 2001;13:140-51. 195. Eaton NR, Krueger RF, Markon KE et al. The structure and predictive validity of the internalizing disorders. J Abnorm Psychol 2013;122: 86-92. 196. Krueger RF, Markon KE, Patrick CJ et al. Externalizing psychopathology in adulthood: a dimensional-spectrum conceptualization and its implications for DSM-V. J Abnorm Psychol 2005;114:537-50. 197. Carragher N, Krueger RF, Eaton NR et al. ADHD and the externalizing spectrum: direct comparison of categorical, continuous, and hybrid models of liability in a nationally representative sample. Soc Psychiatry Psychiatr Epidemiol 2014;49:1307-17. 198. Kotov R, Chang SW, Fochtmann LJ et al. Schizophrenia in the internalizing-externalizing framework: a third dimension? Schizophr Bull 2011;37:1168-78. 199. Kotov R, Krueger RF, Watson D. A paradigm shift in psychiatric classification: the Hierarchical Taxonomy Of Psychopathology (HiTOP). World Psychiatry 2018;17:24-5. 200. Gaebel W, Zaske H, Baumann AE. The relationship between mental illness severity and stigma. Acta Psychiat Scand 2006;113(Suppl. 429):41-5. 201. Grootenboer EM, Giltay EJ, van der Lem R et al. Reliability and validity of the Global Assessment of Functioning Scale in clinical outpatients with depressive disorders. J Eval Clin Pract 2012;18:502-7. 202. Bech P, Boyer P, Germain JM et al. HAM-D17 and HAM-D6 sensitivity to change in relation to desvenlafaxine dose and baseline depression severity in major depressive disorder. Pharmacopsychiatry 2010;43:271-6.